Small Molecule Drug Product Outsourcing

In Q4 2019, ISR asked 176 outsourcers of small molecule drug product manufacturing about the proportion of work allocated across three different approaches to outsourcing: tactical outsourcing, preferred providers, and strategic partnerships. The data show that the largest proportion of work (40%) is allocated to preferred providers, even though 43% of respondents work at companies that do not have preferred provider agreements. To learn more, follow the link to the Small Molecule Drug Product CMO Quality Benchmarking report preview.